Open access · OA
via OpenAlex
Parkinson’s disease biomarkers based on α‐synuclein
Muneera Fayyad, Safa Salim, Nour K. Majbour, Daniel Erskine, Erik Stoops, Brit Mollenhauer, Omar M. A. El‐Agnaf
Journal of Neurochemistry · 2019 · ▲ 157 citations
Abstract
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and is estimated to affect approximately 1-4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease-modifying therapies for Parkinson's disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson's disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non-invasive means is a pressing issue in the field. Since the discovery of α-synuclein (α-syn) as a protein linked to a familial form of Parkinson's disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson's disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson's disease biomarker discovery with a focus on α-synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α-synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. "This article is part of the Special Issue Synuclein."
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/jnc.14809
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Fayyad, M., Salim, S., Majbour, N.K., Erskine, D., Stoops, E., Mollenhauer, B., & El‐Agnaf, O.M.A. (2019). Parkinson’s disease biomarkers based on α‐synuclein. <em>Journal of Neurochemistry</em>. https://doi.org/10.1111/jnc.14809
Vancouver
Fayyad M, Salim S, Majbour NK, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson’s disease biomarkers based on α‐synuclein. Journal of Neurochemistry. 2019. doi:10.1111/jnc.14809.
BibTeX
@article{muneera2019Parkin,
title = {Parkinson’s disease biomarkers based on α‐synuclein},
author = {Muneera Fayyad and Safa Salim and Nour K. Majbour and Daniel Erskine and Erik Stoops and Brit Mollenhauer and Omar M. A. El‐Agnaf},
journal = {Journal of Neurochemistry},
year = {2019},
doi = {10.1111/jnc.14809},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Newcastle University ePrints (Newcastle Univesity) 2019
Preprint · OA
Parkinson's disease biomarkers based on alpha-synuclein
Journal of Neurochemistry 2016
Open access · OA
DNA methylation in Parkinson's disease
npj Parkinson s Disease 2022
Open access · CC-BY
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
Acta Neuropathologica 2007
Citation only
α-Synuclein pathology in the neostriatum in Parkinson’s disease
The Lancet 2009
Citation only
Parkinson's disease
The Lancet 2021
Open access · OA